ザボフロキサシン

説明Zabofloxacin is a quinolone antibiotic originally developed by Dong Wha Pharmaceuticals and licensed to Pacific Beach Biosciences in 2007. In March 2015, Korea’s Ministry of Food and Drug Safety (MFDS) approved zabofloxacin for the treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease (ABE-COPD). In 2016, zabofloxacin gained approval from the USFDA for the treatment of community-acquired pneumonia. ABE-COPD is caused by respiratory tract and pulmonary parenchyma that cause chronic pulmonary inflammation and obstruction in the respiratory tract, which leads to irreversible damage. In the nonclinical evaluation process, zabofloxacin showed strong antibiotic activity on respiratory germs (e.g., Streptococcus pneumonia, S. Haemophilus, S. moraxella) and was the most potent antibacterial agent against penicillin-resistant S. pneumoniae (PRSP) in the murine systemic infection model.